|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Product revenue | |||||
| Service | |||||
| Service and other revenue | |||||
| Total revenue | |||||
| Cost of revenue | |||||
| Product revenue | |||||
| Service | |||||
| Service and other revenue | |||||
| Total cost of revenue | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Goodwill impairment charge | |||||
| Other charges, net | |||||
| Total operating expenses | |||||
| Operating income | |||||
| Interest and other income (expense), net | |||||
| Bargain purchase gain and associated measurement period adjustments | |||||
| Interest and other expense, net | |||||
| Total interest and other income (expense), net | |||||
| Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries | |||||
| Income tax provision | |||||
| Equity in (losses) income of unconsolidated investees, net of tax | |||||
| Consolidated net (loss) income | |||||
| Foreign currency translation adjustments (net of tax of $1.4, $2.1 million and $1.2, respectively) | |||||
| Derivatives designated as hedging instruments (net of tax of ($13.8) , $12.5 , respectively) | |||||
| Pension liability adjustments (net of tax of ($11.8) , ($3.9) and ($1.7) , respectively) | |||||
| Comprehensive income | |||||
| Less: Comprehensive income attributable to noncontrolling interests | |||||
| Less: Comprehensive loss attributable to redeemable noncontrolling interest | |||||
| Comprehensive income attributable to Bruker Corporation | |||||
| Net income attributable to noncontrolling interests in consolidated subsidiaries | |||||
| Net (loss) income attributable to Bruker Corporation | |||||
| Dividends on Series A Mandatory Convertible Preferred Stock | |||||
| Net (loss) income attributable to Bruker Corporation common shareholders | |||||
| Net (loss) income per common share attributable to Bruker Corporation common shareholders: | |||||
| Basic | |||||
| Diluted | |||||
| Weighted average common shares outstanding: | |||||
| Basic | |||||
| Diluted |
Loading...